Nathalie Brun
Nessuna posizione attualmente
Profilo
Nathalie Brun formerly worked at AKKA Technologies SE, as Director-Finance & Administration from 1996 to 2001, Axxès SAS, as Director-Finance & Administration from 2005 to 2007, and ElsaLys Biotech SAS, as Chief Financial Officer from 2017 to 2019.
Ms. Brun received her graduate degree in 1995 from EM Lyon Business School.
Precedenti posizioni note di Nathalie Brun
| Società | Posizione | Fine |
|---|---|---|
| ELSALYS BIOTECH | Direttore Finanziario/CFO | 01/09/2019 |
Axxès SAS
 Axxès SAS Other TransportationTransportation Axxès SAS provides toll and parking fee collection services. The company is headquartered in Lyon, France. | Direttore Finanziario/CFO | 01/12/2007 |
| AKKA TECHNOLOGIES SE | Direttore Finanziario/CFO | 01/04/2001 |
Formazione di Nathalie Brun
| EM Lyon Business School | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
AKKA Technologies SE
 AKKA Technologies SE Miscellaneous Commercial ServicesCommercial Services AKKA Technologies SE engages in the provision of engineering consulting and research and development services in the mobility sector. It operates through the following geographical segments: France, Germany, North America, International, Data Respons, and Other. The firm offers software engineering, systems engineering, and mechanical and thermal engineering solutions. The company was founded by Maurice Ricci on April 1, 1984 and is headquartered in Brussels, Belgium. | Commercial Services |
Axxès SAS
Axxès SAS Other TransportationTransportation Axxès SAS provides toll and parking fee collection services. The company is headquartered in Lyon, France. | Transportation |
ElsaLys Biotech SAS
 ElsaLys Biotech SAS Pharmaceuticals: MajorHealth Technology ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France. | Health Technology |
- Borsa valori
- Insiders
- Nathalie Brun
